- seekingalpha.com
- Posted On 21 November 2026
Capricor reviewing operations as FDA rejects cell therapy
Capricor Therapeutics (CAPR) announced that its operating expenses are under review after the U.S. Food and Drug Administration on Friday declined to approve it...
Source:
seekingalpha.com